TIGIT & The Next Wave of Immune Checkpoint Inhibitors - hear from Compugen, Stanford University, Beacon Targeted Therapies and more!. Whilst the .. Read more TIGIT axis has emerged as an important immune regulator in the cancer immunity cycle, so have a new wave of ICI, including LAG-3 and TIM-3, which are also showing great promise in the clinic. Consider the potential impact of novel ICI on the IO landscape, rationalize combination strategy, and maximize clinical response by leveraging synergistic pathways in this new generation of targets with Compugen Inc. and leaders at Stanford University. Discuss how to advance novel ICI targets and combinations for market approval, and gain an overview of current development, clinical trials, and key players in novel immune checkpoint development. Join this seminar for the latest updates in ICI development, to identify potential combination approaches, and to enhance the immune response to your therapies in the clinic. Hanson Wade's goal is to accelerate progress within organisations and across industries. Our primary method for achieving this is by creating exclusive business conferences that gather together the world's smartest thinkers and doers.
- Share your Experience
More Events From The Organizer
- TIGIT Therapies Digital Consor..26 - 27 Oct 2020Online